BACKGROUND: Elevated pretreatment interferon (IFN) gamma-inducible protein 10 (IP-10/CXCL10) levels are a marker of treatment nonresponse in hepatitis C virus (HCV)-monoinfected patients. We undertook this study to determine if IP-10 is a marker of treatment outcome in HCV/HIV-coinfected patients. METHODS: Nineteen HCV/HIV-coinfected patients were treated with weight-based pegylated (PEG) IFNalpha-2b (1.5 microg/kg) once weekly plus weight-based ribavirin (1000 or 1200 mg) daily for up to 48 weeks. Plasma IP-10, monokine induced by IFNgamma/CXCL9 (Mig), and IFN-inducible T-cell alpha-chemoattractant/CXCL11 (I-TAC) levels were measured by enzyme-linked immunosorbent assay on samples obtained frequently during the first 3 PEG-IFN doses and throughout treatment. RESULTS: Median pretreatment plasma IP-10 (interquartile range [IQR]) levels were significantly lower in virological responders (n=6) at 217 (IQR: 181-301) pg/mL compared with nonresponders (n=13) at 900 (IQR: 628-2048) pg/mL (P=0.002), whereas pretreatment Mig and I-TAC levels did not differ significantly. Plasma IP-10 levels of 400 pg/mL before treatment and on days 7 and 14 could be used to identify likely coinfected PEG-IFN/ribavirin nonresponders. PEG-IFN-induced elevations in IP-10 were greater in virological responders than in nonresponders (approximately 10-fold vs. approximately 4-fold) after the first PEG-IFN dose. CONCLUSIONS: IP-10 may be a biomarker of HCV treatment outcome in difficult-to-treat HCV/HIV-coinfected patients.
BACKGROUND: Elevated pretreatment interferon (IFN) gamma-inducible protein 10 (IP-10/CXCL10) levels are a marker of treatment nonresponse in hepatitis C virus (HCV)-monoinfected patients. We undertook this study to determine if IP-10 is a marker of treatment outcome in HCV/HIV-coinfectedpatients. METHODS: Nineteen HCV/HIV-coinfectedpatients were treated with weight-based pegylated (PEG) IFNalpha-2b (1.5 microg/kg) once weekly plus weight-based ribavirin (1000 or 1200 mg) daily for up to 48 weeks. Plasma IP-10, monokine induced by IFNgamma/CXCL9 (Mig), and IFN-inducible T-cell alpha-chemoattractant/CXCL11 (I-TAC) levels were measured by enzyme-linked immunosorbent assay on samples obtained frequently during the first 3 PEG-IFN doses and throughout treatment. RESULTS: Median pretreatment plasma IP-10 (interquartile range [IQR]) levels were significantly lower in virological responders (n=6) at 217 (IQR: 181-301) pg/mL compared with nonresponders (n=13) at 900 (IQR: 628-2048) pg/mL (P=0.002), whereas pretreatment Mig and I-TAC levels did not differ significantly. Plasma IP-10 levels of 400 pg/mL before treatment and on days 7 and 14 could be used to identify likely coinfected PEG-IFN/ribavirin nonresponders. PEG-IFN-induced elevations in IP-10 were greater in virological responders than in nonresponders (approximately 10-fold vs. approximately 4-fold) after the first PEG-IFN dose. CONCLUSIONS:IP-10 may be a biomarker of HCV treatment outcome in difficult-to-treat HCV/HIV-coinfectedpatients.
Authors: Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert Journal: J Clin Invest Date: 2010-12-22 Impact factor: 14.808
Authors: Lucy Golden-Mason; Kiran M Bambha; Linling Cheng; Charles D Howell; Milton W Taylor; Paul J Clark; Nezam Afdhal; Hugo R Rosen Journal: Hepatology Date: 2011-08-24 Impact factor: 17.425
Authors: Aaron F Carlin; Paula Aristizabal; Qinghua Song; Huan Wang; Matthew S Paulson; Luisa M Stamm; Robert T Schooley; David L Wyles Journal: Hepatology Date: 2015-08-22 Impact factor: 17.425
Authors: A Casrouge; A Bisiaux; L Stephen; M Schmolz; J Mapes; C Pfister; S Pol; V Mallet; M L Albert Journal: Clin Exp Immunol Date: 2012-01 Impact factor: 4.330
Authors: Jason Grebely; Jordan J Feld; Tanya Applegate; Gail V Matthews; Margaret Hellard; Alana Sherker; Kathy Petoumenos; Geng Zang; Ineke Shaw; Barbara Yeung; Jacob George; Suzy Teutsch; John M Kaldor; Vera Cherepanov; Julie Bruneau; Naglaa H Shoukry; Andrew R Lloyd; Gregory J Dore Journal: Hepatology Date: 2013-05-08 Impact factor: 17.425